Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction.
Skinner
J S
JS
Department of Cardiology, Royal Victoria Infirmary, Newcastle upon Tyne, UK. Jane.Skinner@nuth.nhs.uk
Minhas
R
R
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008019:Life Style; D009203:Myocardial Infarction / Q000517:prevention & control*; D009204:Myocardial Revascularization / Q000379:methods; D017410:Practice Guidelines as Topic
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin